2000
DOI: 10.1128/aac.44.2.458-461.2000
|View full text |Cite
|
Sign up to set email alerts
|

In Vitro Activities of Rabeprazole, a Novel Proton Pump Inhibitor, and Its Thioether Derivative Alone and in Combination with Other Antimicrobials against Recent Clinical Isolates of Helicobacter pylori

Abstract: The MICs of rabeprazole sodium (RPZ), a newly developed benzimidazole proton pump inhibitor (PPI), against 133 clinical Helicobacter pylori strains revealed a higher degree of activity than the another two PPIs, lansoprazole and omeprazole. Time-kill curve assays of RPZ, when combined with amoxicillin, clarithromycin, or metronidazole, disclosed that synergistic effects were demonstrated in combination with each antibiotic examined. Moreover, no apparent antagonistic effect appeared among all of the strains te… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
39
0
2

Year Published

2001
2001
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 44 publications
(41 citation statements)
references
References 20 publications
0
39
0
2
Order By: Relevance
“…Although a clinically successful eradication scheme employed seems not to be influenced by the PPI used, clinical differences due to pharmacological properties of the drug have been reported [10,13,14] . Thus, rabeprazole and its metabolite thioether rabeprazole have been proposed to have some advantage because of the higher stability under acid pH and the increased antibacterial activity upon H. pylori as compared with omeprazole and other PPI [15] . Nonetheless, the inclusion of a PPI different than omeprazole in the triple therapy needs more experience to decrease uncertainty in its usefulness for the eradication of H. pylori infection.…”
Section: Discussionmentioning
confidence: 99%
“…Although a clinically successful eradication scheme employed seems not to be influenced by the PPI used, clinical differences due to pharmacological properties of the drug have been reported [10,13,14] . Thus, rabeprazole and its metabolite thioether rabeprazole have been proposed to have some advantage because of the higher stability under acid pH and the increased antibacterial activity upon H. pylori as compared with omeprazole and other PPI [15] . Nonetheless, the inclusion of a PPI different than omeprazole in the triple therapy needs more experience to decrease uncertainty in its usefulness for the eradication of H. pylori infection.…”
Section: Discussionmentioning
confidence: 99%
“…[97,[101][102][103][104][105][106][107] Thus, the MIC range against H. pylori for rabeprazole is considerably lower than that previously reported for omeprazole or lansoprazole. [97,[101][102][103][104][105][106][107][108] Furthermore, in vitro, rabeprazole inhibits H. pylori motility [105,106] and urease activity. [109,110] However, but for some exceptions, rabeprazole monotherapy has not been able to eradicate H. pylori infection.…”
Section: Rabeprazolementioning
confidence: 99%
“…The effect of CaEO against Listeria monocytogenes was assessed in vitro by sequential sampling and counting viable bacteria in the physiological saline solution following the addition of the essential oil according to the method of Kawakami et al 17 with slight modification. For viable counts, each of tubes containing bacterial suspension approximately 108 CFU/ml of L. monocytogenes was inoculated with three different concentrations of the CaEO 2.5, 5 and 7.5 mg/ml in a final volume of 5 ml sterile physiological saline solution and incubated at 37 .…”
Section: Effect Of Essential Oil On Viable Counts Of Bacteriamentioning
confidence: 99%